Sakar has announced a board meeting.

The company secured its second EU Marketing Authorization for an oncology injection targeting colorectal cancer, expanding its portfolio from breast, lung, and prostate cancer treatments.

This approval paves the way for boosted exports and commercialization in Europe from its integrated oncology manufacturing unit.

Several other oncology products are under registration for the EU market, expected to accelerate overseas sales growth.

This milestone enhances Sakar’s presence in the regulated EU oncology segment, supporting its export-driven revenue strategy.